Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting., 9819 [08-794]
Download as PDF
Federal Register / Vol. 73, No. 36 / Friday, February 22, 2008 / Notices
mstockstill on PROD1PC66 with NOTICES
Related Publications:
1. A manuscript directly related to
this technology will be available as soon
as it is accepted for publication.
2. E Calvo. Collagen-platelet
aggregation inhibitor from mosquito
salivary glands. Biacore T100 seminar
series, November 2006, St. Louis,
Missouri.
3. S Yoshida and H Watanabe. Robust
salivary gland-specific transgene
expression in Anopheles stephensi
mosquito. Insect Mol Biol. 2006 Aug;
15(4):403–410.
4. D Sun et al. Expression of
functional recombinant mosquito
salivary apyrase: a potential therapeutic
platelet aggregation inhibitor. Platelets.
2006 May; 17(3):178–184.
Patent Status: U.S. Provisional
Application No. 60/198,629 filed 09 Jul
2007 (HHS Reference No. E–172–2007/
0–US–01); U.S. Provisional Application
No. 60/982,241 filed 24 Oct 2007 (HHS
Reference No. E–172–2007/1–US–01)
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases, Laboratory of
Malaria and Vector Research, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize the platelet aggregation
inhibitor Aegyptin. Please contact Dr.
Jose Ribeiro, Head, Vector Biology
Section, at 301–496–9389 or
jribeiro@niaid.nih.gov for more
information.
Manganese Superoxide Dimutase
VAL16ALA Polymorphism Predicts
Resistance to Doxorubicin Cancer
Therapy
Description of Technology: Cancer is
the second leading cause of death in the
United States and it is estimated that
there will be approximately 600,000
deaths caused by cancer in 2006. Major
drawbacks of the existing cancer
therapies are the interindividual
differences in the response and the
cytotoxic side-effects that are associated
with them. Thus, there is a need to
develop new therapeutic approaches to
optimize treatment and increase patient
survival.
This technology describes the
identification of a manganese
superoxide dismutase (MnSOD)
polymorphism as a novel biomarker for
the prognosis of doxorubicin
therapeutic response in breast cancer
patients, wherein a Val16Ala
polymorphism of MnSOD is indicative
of patient survival. More specifically,
VerDate Aug<31>2005
16:38 Feb 21, 2008
Jkt 214001
patients undergoing doxorubicin
combination therapy with Val/Val, Val/
Ala, and Ala/Ala genotypes had 95.2%,
79%, and 45.5% survival rates,
respectively, in a case study of 70
unselected breast cancer patients.
Carriers of the Ala/Ala genotype had a
highly significantly poorer breast
cancer-specific survival in a
multivariate Cox regression analysis
than carriers of the Val/Val genotype.
This technology can be developed into
an assay to screen for breast cancer
patients who will be responsive to
doxorubicin treatment. Further, as the
MnSOD polymorphism is common in
the population (15% to 20% of patients
have the Ala/Ala genotype), it is a
common risk factor for doxorubicin
therapy. This technology can potentially
be utilized as a screening tool applicable
for all cancer types treated with
doxorubicin.
Applications:
A novel genetic marker that can
predict breast cancer patient survival
with doxorubicin treatment.
A screening test based on MnSOD
Val16Ala genotype that predicts patient
response to doxorubicin cancer therapy,
wherein treatment can be subsequently
individualized according to patient
MnSOD genotype.
Development Status: Future studies
include determining the mechanism in
which the polymorphism modulates
doxorubicin toxicity.
Inventors: Stefan Ambs and Brenda
Boersma (NCI).
Patent Status: U.S. Provisional
Application No. 60/799,788 filed 11
May 2006 (HHS Reference No. E–137–
2006/0–US–01); PCT Application No.
PCT/US2007/068588 filed 09 May 2007
(HHS Reference No. E–137–2006/0–
PCT–02).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Laboratory of Human
Carcinogenesis, Center for Cancer
Research, National Cancer Institute,
National Institutes of Health, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize MnSOD genotyping
assays to assess a patient’s response to
doxorubicin combination therapy.
Please contact John D. Hewes, PhD, at
301–435–3121 or hewesj@mail.nih.gov
for more information.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
9819
Dated: February 15, 2008.
David Sadowski,
Deputy Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. E8–3274 Filed 2–21–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Initial Review Group, Subcommittee
A — Cancer Centers.
Date: April 22–23, 2008.
Time: 8 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crown Plaza Silver Spring, 8777
Georgia Avenue, Silver Spring, MD 20910.
Contact Person: Gail J. Bryant, MD,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd, Room 8107,
MSC 8328, Bethesda, MD 20892–8329, (301)
402–0801, gb30t@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 14, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–794 Filed 2–21–08; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\22FEN1.SGM
22FEN1
Agencies
[Federal Register Volume 73, Number 36 (Friday, February 22, 2008)]
[Notices]
[Page 9819]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 08-794]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act,
as amended (5 U.S.C. Appendix 2), notice is hereby given of the
following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Initial Review
Group, Subcommittee A -- Cancer Centers.
Date: April 22-23, 2008.
Time: 8 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Crown Plaza Silver Spring, 8777 Georgia Avenue, Silver
Spring, MD 20910.
Contact Person: Gail J. Bryant, MD, Scientific Review Officer,
Resources and Training Review Branch, Division of Extramural
Activities, National Cancer Institute, 6116 Executive Blvd, Room
8107, MSC 8328, Bethesda, MD 20892-8329, (301) 402-0801,
gb30t@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 14, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-794 Filed 2-21-08; 8:45 am]
BILLING CODE 4140-01-M